CIK 0000872589 · Large accelerated filer
REGENERON PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- REGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 133444607
- Phone
- 9148477000
- Business address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
- Former names
- REGENERON PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $51,901,544
- in 11 filings, $8.6M under 10b5-1 plans
Net −$51,901,544. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-27 | Landry Robert E EVP Finance CFO | Sale 10b5-1 | −4 | $829.16 | $3K | 32,936 |
| 2023-03-27 | Landry Robert E EVP Finance CFO | Sale 10b5-1 | −7 | $830.01 | $6K | 32,929 |
| 2023-03-27 | Landry Robert E EVP Finance CFO | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −3,000 | 20,337 | ||
| 2023-03-27 | Landry Robert E EVP Finance CFO | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −800 | 0 | ||
| 2023-03-24 | Bassler Bonnie L Director | Option exercise 10b5-1 | +1,240 | $380.95 | $472K | 2,487 |
| 2023-03-24 | Bassler Bonnie L Director | Sale 10b5-1 | −1,240 | $818.00 | $1.0M | 1,247 |
| 2023-03-24 | Bassler Bonnie L Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −1,240 | 2,480 | ||
| 2023-03-23 | VAGELOS P ROY Director | Gift 10b5-1 | −25,000 | 312,578 | ||
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −254 | $800.59 | $203K | 200,250 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −122 | $801.16 | $98K | 200,128 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −1,237 | $802.54 | $993K | 198,891 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −642 | $803.30 | $516K | 198,249 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −254 | $804.38 | $204K | 197,995 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −47 | $805.55 | $38K | 197,948 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −700 | $806.47 | $565K | 197,248 |
| 2023-03-23 | YANCOPOULOS GEORGE President and Chief Scientific | Sale 10b5-1 | −400 | $810.30 | $324K | 196,848 |
| 2023-03-23 | LAROSA JOSEPH J EVP General Counsel and Secret | Option exercise | +10,000 | $270.43 | $2.7M | 34,213 |
| 2023-03-23 | LAROSA JOSEPH J EVP General Counsel and Secret | Shares withheld for taxes | −6,742 | $801.59 | $5.4M | 27,471 |
| 2023-03-23 | LAROSA JOSEPH J EVP General Counsel and Secret | Option exercise · Non-Qualified Stock Option (right to buy) | −10,000 | 0 | ||
| 2023-03-23 | Fenimore Christopher R. SVP Controller | Sale 10b5-1 | −2,192 | $806.47 | $1.8M | 18,409 |
Page 55 of 105 · 2,088 trades